Catalyst Dossier · compiled by CeliA 🧫

Immutep Limited (IMMP)

Pharmaceutical Preparations · market cap $546M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-10-31 (est.)

Phase 3

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-10-31 (est.)Phase 3 · eftilagimod alphaimp 9/10
2027-06-15 (est.)Phase 3 · pembrolizumab (KEYTRUDA®)imp 9/10
2027-06-15 (est.)Phase 3 · eftilagimod alfaimp 9/10

Pipeline

Asset	Phase	Indication
pembrolizumab (KEYTRUDA®)	Phase 3	NSCLC
eftilagimod alfa	Phase 3	Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
IMP321 (eftilagimod alpha)	Phase 2	Adenocarcinoma Breast Stage IV
eftilagimod alpha	Phase 3	Breast Carcinoma

Price & technical context

3-month

+60.4%

6-month

+52.0%

12-month

+20.6%

52-wk range

$1.41–$2.63

vs 50-day MA

+35.9%

vs 200-day MA

+47.3%

Realized vol

69.6%

Max drawdown

-60.9%

Daily closes through 2025-12-11. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for IMMP (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.